The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.
Study Type
OBSERVATIONAL
Enrollment
2,000
The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
Huashan Hospital Affiliated to Fudan University
Shanghai, China
RECRUITINGViral shedding time
time from the first positive testing to the first day of nucleic acid Ct value\> 35 for both ORF1ab and N gene (in two consecutive).
Time frame: up to 28 days
Percentage of the participants who have progression of COVID-19
Percentage of participants who experience these events by Day 28 Progress to severe and/or critical COVID-19; Death from any cause
Time frame: up to 28 days
AEs and SAEs through Day 28
Adverse events and Serious adverse events through Day 28
Time frame: up to 28 days
Percentage of participants who turned negative for SARS-CoV-2
Percentage of participants who turned negative for SARS-COV-2 at Day 3, 5, 7, 10, 14
Time frame: up to 28 days
Time to sustained clinical recovery
Time to sustained clinical recovery
Time frame: up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.